FORM 6 - K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13a - 16 or 15d - 16 of
the Securities Exchange Act of 1934
As of 5/6/2015
Ternium S.A.
(Translation of Registrant's name into English)
Ternium S.A.
29 Avenue de la Porte-Neuve
L-2227 Luxembourg
(352) 2668-3152
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or 40-F.
Form 20-F Ö Form 40-F
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12G3-2(b) under the Securities Exchange Act of 1934.
Yes No Ö
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):
Not applicable
The
attached material is being furnished to the Securities and Exchange Commission
pursuant to Rule 13a-16 and Form 6-K under the Securities Exchange Act of 1934,
as amended.
This
report contains a summary of the resolutions adopted in the annual and
extraordinary general meetings of shareholders of Ternium S.A., both held on May 6, 2015.
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
TERNIUM S.A.
By: /s/ Arturo Sporleder
Name: Arturo Sporleder
Title: Secretary of the
Board of Directors
Dated:
May 6, 2015
Summary of the resolutions adopted in the Annual General Meeting of Shareholders of TERNIUM S.A. (the “Company”) held on May 6, 2015, at 2:30 p.m. (Luxembourg time) (the “Annual Meeting”), at 29, avenue de la Porte-Neuve, L-2227 Luxembourg
Annual Meeting
1. Consideration of the Board of Directors’ and independent auditor’s reports on the Company’s consolidated financial statements. Approval of the Company’s consolidated financial statements as of 31 December 2014 and 2013 and for the years ended 31 December 2014, 2013 and 2012.
The Meeting resolved to approve the Company’s consolidated financial statements as of 31 December 2014 and 2013 and for the years ended 31 December 2014, 2013 and 2012.
2. Consideration of the independent auditor’s report on the Company’s annual accounts. Approval of the Company’s annual accounts as at 31 December 2014.
The Meeting resolved to approve the Company’s annual accounts as at 31 December 2014.
3. Allocation of results and approval of dividend payment for the year ended 31 December 2014.
The Meeting resolved (i) to approve a dividend, payable in U.S. dollars, on 15 May 2015, in the amount of USD 0.09 per share issued and outstanding (or USD 0.9 per ADR), (ii) to authorize the Board of Directors to determine or amend, in its discretion, any of the terms and conditions of such dividend payment, including the applicable record date, (iii) that the aggregate amount of USD 176,676,909.84 (which is net of the Company's shares held by the subsidiary Ternium International Inc.) to be distributed as dividend on 15 May 2015, be paid from the Company’s retained earnings reserve, and (iv) that the loss of the year ended 31 December 2014, be absorbed by the Company’s retained earnings account
4. Discharge of the members of the Board of Directors for the exercise of their mandate during the year ended 31 December 2014.
The Meeting resolved to discharge all those who were members of the Board of Directors during the year ended 31 December 2014, from any liability in connection with the management of the Company’s affairs during such year.
5. Election of the members of the Board of Directors.
The Meeting resolved to reduce the number of members of the Board of Directors to eight and to re-appoint Messrs. Ubaldo Aguirre, Roberto Bonatti, Carlos Alberto Condorelli, Pedro Pablo Kuczynski, Adrian Lajous, Gianfelice Mario Rocca, Paolo Rocca and Daniel Agustin Novegil to the Board of Directors, each to hold office until the next annual general meeting of shareholders that will be convened to decide on the 2015 accounts.
6.
Authorization of the compensation
of members of the Board of Directors.
The Meeting resolved that each of the members of the
Board of Directors receive an amount of USD 85,000.00 as compensation for his
services during the fiscal year 2015, and that the Chairman of the Board of
Directors receive, further, an additional fee of USD 295,000.00; and that each
of the members of the Board of Directors who are members of the Audit Committee
receive an additional fee of USD 55,000.00, and that the Chairman of such Audit
Committee receive, further, an additional fee of USD 10,000.00. In all cases,
the approved compensation will be net of any applicable Luxembourg social
security charges.
7.
Appointment of the independent
auditors for the fiscal year ending 31 December 2015, and approval of their
fees.
The Meeting resolved to (i) appoint PricewaterhouseCoopers, Société
coopérative, Cabinet de révision agréé, as the Company’s independent
auditors for the fiscal year ending 31 December 31, 2015, to be engaged until
the next annual general meeting of shareholders that will be convened to decide
on the 2015 accounts; and (ii) approve the independent auditors’ fees for
audit, audit-related and other services to be rendered during the fiscal year
ending 31 December 2015, broken-down into eight currencies (Argentine Pesos, Brazilian
Reais, Colombian Pesos, Euro, Mexican Pesos, Swiss Francs, Uruguayan Pesos, and
U.S. Dollars), up to a maximum amount for each currency equal to ARS
15,769,259.00; BRL 22,476.00; COP 243,174,993.00; EUR 582,666.00; MXN
12,582,031.00; CHF 27,500.00; UYU 2,645,081.00 and USD 162,400.00, and to
authorize the Audit Committee to approve any increase or reallocation of the
independent auditors’ fees as may be necessary, appropriate or desirable under
the circumstances.
8.
Authorization to the Company, or any
subsidiary, to from time to time purchase, acquire or receive securities of the
Company, in accordance with Article 49-2 of the Luxembourg law of 10 August
1915 and with applicable laws and regulations.
The Meeting resolved to (i) renew the authorization to the Company
and to the Company’s subsidiaries to acquire, from time to time, Shares,
granted by the Annual General Meeting of Shareholders held on 3 June 2010, (ii)
grant all powers to the Board of Directors and to the board of directors or
other governing bodies of the Company’s subsidiaries, in each case with powers
to delegate in accordance with applicable laws, the Articles or the articles of
association or other applicable organizational documents of the relevant
Company’s subsidiary, to decide on and implement this authorization, to define,
if necessary, the terms and procedures for carrying out any purchase,
acquisition or reception of Shares, and, in particular, to place any stock
exchange orders, conclude any agreements, including, without limitation, for
keeping registers of purchases and sales of Shares, make any declarations to
the applicable regulatory authorities, carry out all formalities and,
generally, do all such other acts and things as may be necessary, appropriate
or desirable for the purposes aforesaid; and (iii) authorize the Board of
Directors to delegate to its Chairman, with the latter having the option to
sub-delegate to any other person(s), the performance of the actions entrusted
to the Board of Directors, pursuant to, or in connection with, this
authorization
9.
Authorization to the Board of
Directors to delegate the day-to-day management of the Company’s business to
one or more of its members
The Meeting resolved to authorize the Board of Directors to delegate
the management of the Company’s day-to-day business and the authority to
represent and bind the Company with his sole signature in such day-to-day
management to Mr. Daniel Agustin Novegil, and to appoint Mr. Novegil as Chief
Executive Officer (Administrateur Délégué) of the Company.
10. Authorization to the Board of Directors to appoint one or more of
its members as the Company’s attorney-in-fact.
The Meeting
resolved to authorize the Board of Directors to appoint any or all members of
the Board of Directors from time to time as the Company’s attorney-in-fact,
delegating to such directors any management powers (including, without
limitation, any day-to-day management powers) to the extent the Board of
Directors may deem appropriate in connection therewith, this authorization to
be valid until expressly revoked by the Company’s General Shareholders Meeting;
it being understood, for the avoidance of doubt, that this authorization does
not impair nor limit in any way the powers of the Board of Directors to appoint
any non-members of the Board of Directors as attorneys-in-fact of the Company
pursuant to the provisions of article 10.1(iii) of the Articles
Summary of the
resolutions adopted in the Annual Extraordinary General Meeting of Shareholders
of TERNIUM S.A. (the “Company”) held on May 6, 2015, at 2:30 p.m. (Luxembourg
time) (the “Annual Meeting”), at 29, avenue de la Porte-Neuve, L-2227
Luxembourg
Annual
Extraordinary General Meeting
1. Decision
on the renewal of the authorized share capital of the Company and related
authorizations and waivers by:
a. the
renewal of the validity period of the Company’s authorized share capital for a
period starting on the date of the Extraordinary General Meeting of
Shareholders and ending on the fifth anniversary of the date of the publication
in the Mémorial of the deed recording the minutes of such meeting;
b. the
renewal of the authorization to the Board of Directors, or any delegate(s) duly
appointed by the Board of Directors, for a period starting on the date of the
Extraordinary General Meeting of Shareholders and ending on the fifth
anniversary of the date of the publication in the Mémorial of the deed recording
the minutes of such meeting, from time to time to issue shares within the
limits of the authorized share capital against contributions in cash,
contributions in kind or by way of incorporation of available reserves at such
times and on such terms and conditions, including the issue price, as the Board
of Directors or its delegate(s) may in its or their discretion resolve;
c. the
renewal of the authorization to the Board of Directors, for a period starting
on the date of the Extraordinary General Meeting of Shareholders and ending on
the fifth anniversary of the date of the publication in the Mémorial of the
deed recording the minutes of such meeting, to waive, suppress or limit any
pre-emptive subscription rights of shareholders provided for by law to the
extent it deems such waiver, suppression or limitation
advisable for any issue or issues of shares within the authorized share
capital; waiver of any pre-emptive subscription rights provided for by law and
related procedures;
d. the
decision that for as long as (but only for as long as) the shares of the
Company are listed on a regulated market, any issuance of shares for cash
within the limits of the authorized share capital shall be subject by provision
of the Company’s articles of association to the pre-emptive subscription rights
of the then existing shareholders, except in the following cases (in which
cases no pre-emptive rights shall apply):
i. any issuance of shares for, within, in
conjunction with or related to, an initial public offering of the shares of the
Company on one or more regulated markets (in one or more instances); and
ii. any issuance of shares against a
contribution other than in cash; and
iii. any issuance of shares upon conversion of
convertible bonds or other instruments convertible into shares of the Company;
provided, however, that the pre-emptive subscription rights of the then
existing shareholders shall apply by provision of the Company’s articles of
association in connection with any issuance of convertible bonds or other
instruments convertible into shares of the Company for cash; and
iv. any issuance of shares (including by way
of free shares or at discount), up to an amount of 1.5% of the issued share
capital of the Company, to directors, officers, agents, employees of the
Company, its direct or indirect subsidiaries, or its Affiliates (as such term
is defined in the Company’s articles of association) (collectively, the
“Beneficiaries”), including without limitation the direct issue of shares or
upon the exercise of options, rights convertible into shares, or similar
instruments convertible or exchangeable into shares issued for the purpose of
compensation or incentive of the Beneficiaries or in relation thereto (which
the Board of Directors shall be authorized to issue upon such terms and
conditions as it deems fit).
e. the
acknowledgement and approval of the report of the Board of Directors in
relation with the authorized share capital and the proposed authorizations to
the Board of Directors with respect to any issuance of shares within the
authorized share capital while suppressing any pre-emptive subscription rights
of existing shareholders under law and related waiver; and
f. the
amendment of article 5 of the articles of association of the Company to reflect
the resolutions on this item of the agenda.
The Meeting
resolved:
To renew the
validity period of the Company’s authorized share capital for a period starting
on the date of this Meeting and ending on the fifth anniversary of the date of
the publication in the Mémorial of the deed recording the minutes of this
Meeting.
To renew the
authorization to the Board of Directors, or any delegate(s) duly appointed by
the Board of Directors, for a period starting on the date of this Meeting and
ending on the fifth anniversary of the date of the publication in the Mémorial
of the deed recording the minutes of this Meeting, from time to time, to issue
shares within the limits of the authorized share capital against contributions
in cash, contributions in kind or by way of incorporation of available reserves
at such times and on such terms and
conditions, including the issue price, as the Board of Directors or its delegate(s) may in its or their discretion resolve.
To renew the authorization to the Board of Directors, for a period starting on the date of this Meeting and ending on the fifth anniversary of the date of the publication in the Mémorial of the deed recording the minutes of this Meeting, to waive, suppress or limit any pre-emptive subscription rights of shareholders provided for by law to the extent it deems such waiver, suppression or limitation advisable for any issue or issues of shares within the authorized share capital and further resolved to waive any preemptive subscription rights provided for by law and related procedures.
That for so long as (but only for so long as) the shares of the Company are listed on a regulated market, any issuance of shares for cash, within the limits of the authorized share capital, shall be subject by provision of the Company’s articles of association to the pre-emptive subscription rights of the then existing shareholders, except in the following cases (in which cases no pre-emptive rights shall apply):
i. any issuance of shares for, within, in conjunction with or related to, an initial public offering of the shares of the Company on one or more regulated markets (in one or more instances); and
ii. any issuance of shares against a contribution other than in cash; and
iii. any issuance of shares upon conversion of convertible bonds or other instruments convertible into shares of the Company; provided, however, that the pre-emptive subscription rights of the then existing shareholders shall apply by provision of the Company’s articles of association in connection with any issuance of convertible bonds or other instruments convertible into shares of the Company for cash; and
iv. any issuance of shares (including by way of free shares or at discount), up to an amount of 1.5% of the issued share capital of the Company, to directors, officers, agents, employees of the Company, its direct or indirect subsidiaries, or its Affiliates (as such term is defined in the Company’s articles of association) (collectively, the “Beneficiaries), including without limitation the direct issue of shares or upon the exercise of options, rights convertible into shares, or similar instruments convertible or exchangeable into shares issued for the purpose of compensation or incentive of the Beneficiaries or in relation thereto (which the Board of Directors shall be authorized to issue upon such terms and conditions as it deems fit).
To acknowledge and approve the report of the Board of Directors dated 18 February 2015, in relation with the authorized share capital and the proposed authorizations to the Board of Directors with respect to any issuance of shares within the authorized share capital while suppressing any pre-emptive subscription rights of existing shareholders under law and related waiver. Such report of the Board of Directors shall remain annexed to the present deed to be registered therewith.
To approve the amendment of article 5 of the Company’s articles of association to reflect the resolutions on the agenda, so that articles 5.2. (i), 5.2. (ii) and 5.2. (iii) of the articles of association of the Company shall read as follows:
”5.2. (i) The Company’s authorized share capital shall be three billion five hundred million US dollars (USD 3,500,000,000), including the issued share capital, represented by three billion five hundred million (3,500,000,000) shares with a par value of one U.S. dollar per share. The Company’s authorized share
capital (and any
authorization granted to the Board of Directors in relation thereto) shall be
valid from 6 May 2015 until the fifth anniversary of the date of publication of
the deed of the extraordinary General Shareholders’ Meeting held on 6 May 2015
in the Mémorial.
(ii) The Board of Directors, or any delegate(s) duly appointed by
the Board of Directors, may from time to time, for a period starting on the
Extraordinary General Meeting of Shareholders held on 6 May 2015 and ending on
the fifth anniversary of the date of the publication in the Mémorial of the
deed recording the minutes of such meeting, issue shares within the limits of
the authorized share capital against contributions in cash, contributions in
kind or by way of incorporation of available reserves at such times and on such
terms and conditions, including the issue price, as the Board of Directors or
its delegate(s) may in its or their discretion resolve.
The General Shareholders’ Meeting has authorised the Board of
Directors, for a period starting on the date of the Extraordinary General
Meeting of Shareholders held on 6 May 2015 and ending on the fifth anniversary
of the date of the publication in the Mémorial of the deed recording the
minutes of such meeting, to waive, suppress or limit any pre-emptive
subscription rights of shareholders provided for by law to the extent it deems
such waiver, suppression or limitation advisable for any issue or issues of
shares within the authorized share capital, and has waived any pre-emptive
subscription rights provided for by law and related procedures;
(iii) For as long as (but only for as long as) the shares of the
Company are listed on a regulated market, any issuance of shares for cash
within the limits of the authorized share capital shall be subject by provision
of these articles of association to the pre-emptive subscription rights of the
then existing shareholders, except in the following cases (in which cases no
pre-emptive rights shall apply):
(a) any issuance of shares for, within, in conjunction with or
related to, an initial public offering of the shares of the Company on one or
more regulated markets (in one or more instances); and
(b) any issuance of shares against a contribution other than in
cash; and
(c) any issuance of shares upon conversion of convertible bonds or
other instruments convertible into shares of the Company; provided, however,
that the pre-emptive subscription rights of the then existing shareholders
shall apply by provision of the Company’s articles of association in connection
with any issuance of convertible bonds or other instruments convertible into
shares of the Company for cash; and
(d) any issuance of shares (including by way of free
shares or at discount), up to an amount of 1.5% of the issued share capital of
the Company, to directors, officers, agents, employees of the Company, its
direct or indirect subsidiaries, or its Affiliates (collectively, the
“Beneficiaries”), including without limitation the direct issue of shares or
upon the exercise of options, rights convertible into shares, or similar
instruments convertible or exchangeable into shares issued for the purpose of
compensation or incentive of the Beneficiaries or in relation thereto (which
the Board of Directors shall be authorized to issue upon such terms and
conditions as it deems fit).”
Ternium (NYSE:TX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ternium (NYSE:TX)
Historical Stock Chart
From Apr 2023 to Apr 2024